Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models

Neuroscience

Volumn 209, Issue , 2012, Pages 136-143

  Audet, J N ^a   Soucy, G ^a   Julien, J P ^a  

^a Université Laval   (Canada)

Author keywords

ALS; Methylene blue; Neuroinflammation; Superoxide dismutase; TDP 43

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; LITHIUM SALT; METHYLENE BLUE; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIFESPAN; MONOTHERAPY; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FOLDING; REFLEX; SCORING SYSTEM; TRANSGENIC MOUSE; UBIQUITINATION; WESTERN BLOTTING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; IMMUNOHISTOCHEMISTRY; LITHIUM; METHYLENE BLUE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84859265002     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.12.047     Document Type: Article

References (59)

1. Aggarwal S.P., Zinman L., Simpson E., McKinley J., Jackson K.E., Pinto H., Kaufman P., Conwit R.A., Schoenfeld D., Shefner J., Cudkowicz M. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488.
2. Almer G., Vukosavic S., Romero N., Przedborski S. Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999, 72:2415-2425.
3. Anneser J.M., Cookson M.R., Ince P.G., Shaw P.J., Borasio G.D. Glial cells of the spinal cord and subcortical white matter up-regulate neuronal nitric oxide synthase in sporadic amyotrophic lateral sclerosis. Exp Neurol 2001, 171:418-421.
4. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006, 351:602-611.
5. Atamna H., Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis 2010, 20(Suppl 2):S439-S452.
6. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008, 22:703-712.
7. Bahremand A., Nasrabady S.E., Ziai P., Rahimian R., Hedayat T., Payandemehr B., Dehpour A.R. Involvement of nitric oxide-cGMP pathway in the anticonvulsant effects of lithium chloride on PTZ-induced seizure in mice. Epilepsy Res 2010, 89:295-302.
8. Barber S.C., Shaw P.J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010, 48:629-641.
9. Baumer D., Ansorge O., Almeida M., Talbot K. The role of RNA processing in the pathogenesis of motor neuron degeneration. Expert Rev Mol Med 2010, 12:e21.
10. Bogaert E., d'Ydewalle C., Van Den Bosch L. Amyotrophic lateral sclerosis and excitotoxicity: from pathological mechanism to therapeutic target. CNS Neurol Disord Drug Targets 2010, 9:297-304.
11. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
12. Bosco D.A., Morfini G., Karabacak N.M., Song Y., Gros-Louis F., Pasinelli P., Goolsby H., Fontaine B.A., Lemay N., McKenna-Yasek D., Frosch M.P., Agar J.N., Julien J.P., Brady S.T., Brown R.H. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010, 13:1396-1403.
13. Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
14. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
15. Callaway N.L., Riha P.D., Bruchey A.K., Munshi Z., Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav 2004, 77:175-181.
16. Cha C.I., Kim J.M., Shin D.H., Kim Y.S., Kim J., Gurney M.E., Lee K.W. Reactive astrocytes express nitric oxide synthase in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation. Neuroreport 1998, 9:1503-1506.
17. Chattopadhyay M., Valentine J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal 2009, 11:1603-1614.
18. Chio A., Borghero G., Calvo A., Capasso M., Caponnetto C., Corbo M., Giannini F., Logroscino G., Mandrioli J., Marcello N., Mazzini L., Moglia C., Monsurrò M.R., Mora G., Patti F., Perini M., Pietrini V., Pisano F., Pupillo E., Sabatelli M., Salvi F., Silani V., Simone I.L., Sorarù G., Tola M.R., Volanti P., Beghi E. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010, 75:619-625.
19. Clifton J., Leikin J.B. Methylene blue. Am J of Ther 2003, 10:289-291.
20. Eroglu L., Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res 1997, 36:381-385.
21. Feng H.L., Leng Y., Ma C.H., Zhang J., Ren M., Chuang D.M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008, 155:567-572.
22. Fornai F., Longone P., Cafaro L., Kastsiuchenka O., Ferrucci M., Manca M.L., Lazzeri G., Spalloni A., Bellio N., Lenzi P., Modugno N., Siciliano G., Isidoro C., Murri L., Ruggieri S., Paparelli A. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008, 105:2052-2057.
23. Forsberg K., Jonsson P.A., Andersen P.M., Bergemalm D., Graffmo K.S., Hultdin M., Jacobsson J., Rosquist R., Marklund S.L., Brännström T. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010, 5:e11552.
24. Gill A., Kidd J., Vieira F., Thompson K., Perrin S. No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One 2009, 4:e6489.
25. Gros-Louis F., Soucy G., Larivière R., Julien J.P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010, 113:1188-1199.
26. Gurney M.E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 1997, 152(Suppl 1):S67-S73.
27. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
28. Johnson B.S., Snead D., Lee J.J., McCaffery J.M., Shorter J., Gitler A.D. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009, 284:20329-20339.
29. Lagier-Tourenne C., Polymenidou M., Cleveland D.W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010, 19:R46-R64.
30. Lougheed R., Turnbull J. Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS One 2011, 6:e23141.
31. McComas A.J., Upton A.R., Sica R.E. Motoneurone disease and ageing. Lancet 1973, 2:1477-1480.
32. Medina D.X., Caccamo A., Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011, 21:140-149.
33. Miclescu A., Sharma H.S., Martijn C., Wiklund L. Methylene blue protects the cortical blood-brain barrier against ischemia/reperfusion-induced disruptions. Crit Care Med 2010, 38:2199-2206.
34. Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007, CD001447.
35. Narsapur S.L., Naylor G.J. Methylene blue. A possible treatment for manic depressive psychosis. J Affect Disord 1983, 5:155-161.
36. Toxicology and carcinogenesis studies of methylene blue trihydrate (cas no. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 2008, 1-224. National Toxicology Program.
37. Naylor G.J., Dick D.A., Johnston B.B., Hopwood S.E., Dick E.G., Smith A.H., Kay D. Possible explanation for therapeutic action of lithium, and a possible substitute (methylene-blue). Lancet 1981, 2:1175-1176.
38. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
39. Orrell R.W. Motor neuron disease: systematic reviews of treatment for ALS and SMA. Br Med Bull 2010, 93:145-159.
40. Peter C., Hongwan D., Küpfer A., Lauterburg B.H. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000, 56:247-250.
41. Pizzasegola C., Caron I., Daleno C., Ronchi A., Minoia C., Carrì M.T., Bendotti C. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph Lateral Scler 2009, 10:221-228.
42. Pizzuti A., Petrucci S. Mitochondrial disfunction as a cause of ALS. Arch Ital Biol 2011, 149:113-119.
43. Prudencio M., Hart P.J., Borchelt D.R., Andersen P.M. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet 2009, 18:3217-3226.
44. Riha P.D., Rojas J.C., Gonzalez-Lima F. Beneficial network effects of methylene blue in an amnestic model. Neuroimage 2011, 54:2623-2634.
45. Sasaki S., Shibata N., Iwata M. Neuronal nitric oxide synthase immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol 2001, 101:351-357.
46. Sasaki S., Warita H., Abe K., Iwata M. Neuronal nitric oxide synthase (nNOS) immunoreactivity in the spinal cord of transgenic mice with G93A mutant SOD1 gene. Acta Neuropathol 2002, 103:421-427.
47. Schirmer R.H., Adler H., Pickhardt M., Mandelkow E. Lest we forget you-methylene blue. Neurobiol Aging 2011, 32(2325). e2327-2316.
48. Shin J.H., Cho S.I., Lim H.R., Lee J.K., Lee Y.A., Noh J.S., Joo I.S., Kim K.W., Gwag B.J. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol Pharmacol 2007, 71:965-975.
49. Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., Julien J.P. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011, 134:2610-2626.
50. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005, 280:7614-7623.
51. Ticozzi N., Ratti A., Silani V. Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. CNS Neurol Disord Drug Targets 2010, 9:285-296.
52. Turner B.J., Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008, 85:94-134.
53. Urushitani M., Sik A., Sakurai T., Nukina N., Takahashi R., Julien J.P. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006, 9:108-118.
54. Wang J., Xu G., Li H., Gonzales V., Fromholt D., Karch C., Copeland N.G., Jenkins N.A., Borchelt D.R. Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation. Hum Mol Genet 2005, 14:2335-2347.
55. Wen Y., Li W., Poteet E.C., Xie L., Tan C., Yan L.J., Ju X., Liu R., Qian H., Marvin M.A., Goldberg M.S., She H., Mao Z., Simpkins J.W., Yang S.H. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem 2011, 286:16504-16515.
56. Wiklund L., Basu S., Miclescu A., Wiklund P., Ronquist G., Sharma H.S. Neuro- and cardioprotective effects of blockade of nitric oxide action by administration of methylene blue. Ann N Y Acad Sci 2007, 1122:231-244.
57. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996, 93:11213-11218.
58. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
59. Yamashita M., Nonaka T., Arai T., Kametani F., Buchman V.L., Ninkina N., Bachurin S.O., Akiyama H., Goedert M., Hasegawa M. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009, 583:2419-2424.